Roberts Glore & Co. Inc. IL Buys Shares of 1,716 Cencora, Inc. $COR

Roberts Glore & Co. Inc. IL purchased a new stake in Cencora, Inc. (NYSE:COR) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 1,716 shares of the company’s stock, valued at approximately $486,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kemnay Advisory Services Inc. acquired a new position in Cencora in the fourth quarter valued at approximately $25,000. Oakworth Capital Inc. purchased a new position in Cencora in the fourth quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new stake in Cencora during the fourth quarter worth $27,000. Elevation Wealth Partners LLC increased its stake in Cencora by 506.2% during the second quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock worth $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Archer Investment Corp raised its position in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In other news, Director Lauren M. Tyler acquired 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The shares were acquired at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the acquisition, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Elizabeth S. Campbell sold 11,300 shares of Cencora stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.38% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on COR. Royal Bank Of Canada initiated coverage on Cencora in a report on Wednesday, August 19th. They set a “sector perform” rating and a $330.00 price target for the company. Robert W. Baird set a $370.00 price target on shares of Cencora in a research note on Thursday, August 6th. Barclays decreased their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Morgan Stanley increased their price objective on shares of Cencora from $342.00 to $346.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Wells Fargo & Company boosted their target price on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $370.85.

Cencora Trading Up 1.4%

COR opened at $328.28 on Wednesday. The business has a fifty day moving average price of $304.37 and a 200 day moving average price of $311.24. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The stock has a market capitalization of $62.65 billion, a price-to-earnings ratio of 24.39, a PEG ratio of 1.86 and a beta of 0.57.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%.Cencora’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter last year, the company earned $4.00 EPS. Sell-side analysts expect that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora declared that its board has approved a share repurchase plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 17.83%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.